Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy
This study has been terminated.
Sponsor:
Medical Research Laboratories International
Information provided by:
Medical Research Laboratories International
ClinicalTrials.gov Identifier:
NCT00080132
First received: March 23, 2004
Last updated: June 23, 2005
Last verified: April 2005
Tracking Information | |
---|---|
First Received Date ICMJE | March 23, 2004 |
Last Updated Date | June 23, 2005 |
Start Date ICMJE | October 2004 |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE | |
Original Primary Outcome Measures ICMJE | |
Change History | Complete list of historical versions of study NCT00080132 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy |
Official Title ICMJE | An Open-Label, Dose-Escalating Efficacy and Safety Study of Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy |
Brief Summary | The purpose of this study is to determine if implitapide is effective in lowering triglyceride (TG) levels in patients with Fredrickson Type I or V hypertriglyceridemia where the maximum tolerable medication and diet were not sufficient. |
Detailed Description | |
Study Type ICMJE | Interventional |
Study Phase | Phase 2 |
Study Design ICMJE | Endpoint Classification: Safety/Efficacy Study Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE | Hypertriglyceridemia |
Intervention ICMJE | Drug: implitapide |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Terminated |
Enrollment ICMJE | 50 |
Completion Date | April 2005 |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria: In order to participate in this study, patients must meet all of the following inclusion criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 8 Years to 70 Years |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States, Netherlands, Norway |
Administrative Information | |
NCT Number ICMJE | NCT00080132 |
Other Study ID Numbers ICMJE | MRL 2002-003 |
Has Data Monitoring Committee | |
Responsible Party | |
Study Sponsor ICMJE | Medical Research Laboratories International |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Medical Research Laboratories International |
Verification Date | April 2005 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |